Denali Therapeutics Inc. Common Stock (DNLI) is a publicly traded Healthcare sector company. As of May 21, 2026, DNLI trades at $18.52 with a market cap of $2.92B and a P/E ratio of -6.34. DNLI moved +3.92% today. Year to date, DNLI is +17.54%; over the trailing twelve months it is +31.77%. Its 52-week range spans $10.57 to $33.33. Analyst consensus is strong buy with an average price target of $35.91. Rallies surfaces DNLI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes DNLI SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $18.52 |
| Market Cap | $2.92B |
| P/E Ratio | -6.34 |
| EPS | $-2.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.33 |
| 52-Week Low | $10.57 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-512.54M |
| Gross Margin | 0.00% |
14 analysts cover DNLI: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.91.